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For an effective antimalarial therapy, maintenance of
antimalarial drug concentrations well above minimum
parasiticidal concentration for certain time duration is
required in the target compartments (eg., blood, liver).
On the other hand, malaria parasite infection may affect
few physiological functions (eg., hepatic metabolism,
protein binding) that may affect the pharmacokinetics
and tissue disposition of antimalarial drugs. The altered
PK in turn can affect the concentrations of the drugs
and consequently their efficacy. Therefore, this work
was undertaken to understand whether there is any dif-
ference in the pharmacokinetics (PK) of currently
approved/available antimalarial drugs between malaria
patients and healthy subjects.
The pharmacokinetic data of approved drugs was
obtained from various public resources and the data was
compiled for absorption, distribution, metabolism and
elimination (ADME) properties. These ADME properties
were further analyzed against the information available on
reported physiological changes (e.g. reduced hepatic blood
flow in patients, changes in CYP enzyme levels, etc.) to
understand the possible contributing factors for potential
alterations in the pharmacokinetics of drugs in patients.
Pre-clinical information available for these drugs were also
retrieved and used for the present investigation.
The results indicated that there was a significant altera-
tion in the pharmacokinetic properties of most of the cur-
rently available/ approved antimalarial drugs in malarial
patients compared to healthy subjects. The correlation
analysis indicated that physiological changes such as hepa-
tic blood flow, CYP enzyme expression/activity and
protein binding may be the potential reasons for the
observed differences. This analysis could be useful to envi-
sage changes in the PK properties of the drugs based on
their ADME properties and further aid in the development
of future antimalarial drugs.
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